Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
THAMES VENTURES VCT 2 PLCLEI: 21380035MV1VRYEXPR95 07 AUGUST 2024CORRECTION - FINAL RESULTS FOR THE YEAR ENDED 31 MARCH 2024 The Board notes that the announcement of the Company’s Annual Results,...
-
LONDON and NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
-
THAMES VENTURES VCT 2 PLCLEI: 21380035MV1VRYEXPR95 31 JULY 2024FINAL RESULTS FOR THE YEAR ENDED 31 MARCH 2024 Thames Ventures VCT 2 plc, managed by Foresight Group LLP, today announces the final...
-
Ottawa, July 29, 2024 (GLOBE NEWSWIRE) -- The global protein labeling market size is predicted to increase from USD 2.46 billion in 2023 to approximately USD 5.12 billion by 2032, a study published...
-
New Delhi, July 25, 2024 (GLOBE NEWSWIRE) -- The global acetonitrile market is projected to reach valuation of US$ 626.6 million by 2032, up from US$ 390.3 million in 2023, growing at a CAGR of 5.4%...
-
Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution
– ARCALYST® (rilonacept) Q2 2024 net product revenue of $103.4 million, representing 90% year-over-year growth –– ARCALYST 2024 expected net product revenue increased to $405 - $415 million...
-
NEW YORK, July 20, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB) and certain officers. ...
-
Dublin, July 19, 2024 (GLOBE NEWSWIRE) -- The "China Condom Market Size, Share & Trends Analysis By Material Type (Latex, Non-latex), Product (Male Condom, Female Condom), Distribution Channel...
-
NEW YORK, July 12, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB) and certain officers. ...
-
Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024OK-101 is believed to be the first IND clearance granted by FDA for a drug to begin...